How many drugs treat Otitis externa?

Drug Landscape tracks 10 marketed treatments for Otitis externa (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/otitis-externa.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Otitis externa — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Otitis externa (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Otitis externa, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Galzin	ZINC ACETATE	Eton	zinc acetate		1980-01-01
Verdeso	DESONIDE	Padagis Us	Corticosteroid [EPC]	Glucocorticoid receptor	1972-01-01
Coly-Mycin S	tonzonium	Par Sterile Products	tonzonium	Insulin-degrading enzyme	1962-01-01
Coly-Mycin S	COLISTIN	Par Sterile Products	colistin	Melanocortin receptor 3	1962-01-01
Hydrocortisone And Acetic Acid	ACETIC ACID	Hikma	acetic acid	Tyrosine-protein kinase Lck	1960-01-01
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Cortisporin	POLYMYXIN B	Pfizer	Polymyxin-class Antibacterial		1957-01-01
Cortisporin	NEOMYCIN	Pfizer	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 1	1957-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Otitis externa
Par Sterile Products · 2 drugs in Otitis externa
Pfizer · 2 drugs in Otitis externa
Poitiers University Hospital · 2 drugs in Otitis externa
Eton · 1 drug in Otitis externa
Generic (originally Merck) · 1 drug in Otitis externa
Generic (originally Merck/Upjohn) · 1 drug in Otitis externa
Hikma · 1 drug in Otitis externa
Padagis Us · 1 drug in Otitis externa
Parkedale · 1 drug in Otitis externa
University of Zurich · 1 drug in Otitis externa
Assistance Publique - Hôpitaux de Paris · 1 drug in Otitis externa

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Otitis externa:

Cite this brief

Drug Landscape (2026). Otitis externa — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/otitis-externa. Accessed 2026-06-10.

Otitis externa full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing